MX386793B - Vacunas individualizadas para el cancer. - Google Patents

Vacunas individualizadas para el cancer.

Info

Publication number
MX386793B
MX386793B MX2016009082A MX2016009082A MX386793B MX 386793 B MX386793 B MX 386793B MX 2016009082 A MX2016009082 A MX 2016009082A MX 2016009082 A MX2016009082 A MX 2016009082A MX 386793 B MX386793 B MX 386793B
Authority
MX
Mexico
Prior art keywords
cancer
tumor
patient
relates
present
Prior art date
Application number
MX2016009082A
Other languages
English (en)
Spanish (es)
Inventor
Bernhard Renard
Cedrik Britten
Jan Diekmann
Graaf Johannes Hendrikus De
John Castle
Martin Löwer
Michael Koslowski
Mustafa Diken
Sebastian Kreiter
Tana Omokoko
Ugur Sahin
Original Assignee
BioNTech SE
Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2011/002576 external-priority patent/WO2012159643A1/en
Application filed by BioNTech SE, Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh filed Critical BioNTech SE
Publication of MX386793B publication Critical patent/MX386793B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/70—Machine learning, data mining or chemometrics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Epidemiology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Data Mining & Analysis (AREA)
  • Software Systems (AREA)
  • Evolutionary Computation (AREA)
  • Databases & Information Systems (AREA)
  • Artificial Intelligence (AREA)
  • Computer Vision & Pattern Recognition (AREA)
MX2016009082A 2011-05-24 2012-05-23 Vacunas individualizadas para el cancer. MX386793B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2011/002576 WO2012159643A1 (en) 2011-05-24 2011-05-24 Individualized vaccines for cancer
EP2012000006 2012-01-02
PCT/EP2012/002209 WO2012159754A2 (en) 2011-05-24 2012-05-23 Individualized vaccines for cancer

Publications (1)

Publication Number Publication Date
MX386793B true MX386793B (es) 2025-03-19

Family

ID=46148823

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2016009082A MX386793B (es) 2011-05-24 2012-05-23 Vacunas individualizadas para el cancer.
MX2013013659A MX360823B (es) 2011-05-24 2012-05-23 Vacunas individualizadas para el cancer.
MX2020011767A MX2020011767A (es) 2011-05-24 2013-11-22 Vacunas individualizadas para el cancer.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2013013659A MX360823B (es) 2011-05-24 2012-05-23 Vacunas individualizadas para el cancer.
MX2020011767A MX2020011767A (es) 2011-05-24 2013-11-22 Vacunas individualizadas para el cancer.

Country Status (23)

Country Link
US (3) US10738355B2 (enExample)
JP (6) JP6444171B2 (enExample)
CN (3) CN111286537A (enExample)
AU (4) AU2012261237B2 (enExample)
BR (1) BR112013029834A8 (enExample)
CA (1) CA2836494C (enExample)
DK (3) DK2714071T3 (enExample)
ES (4) ES2746233T3 (enExample)
FI (2) FI4223311T3 (enExample)
HR (3) HRP20230443T1 (enExample)
HU (3) HUE062102T2 (enExample)
LT (4) LT4223311T (enExample)
MX (3) MX386793B (enExample)
NZ (2) NZ742420A (enExample)
PL (2) PL4223311T3 (enExample)
PT (4) PT3892295T (enExample)
RS (3) RS64230B1 (enExample)
RU (1) RU2670745C9 (enExample)
SG (2) SG193553A1 (enExample)
SI (3) SI4223311T1 (enExample)
SM (3) SMT202500304T1 (enExample)
WO (1) WO2012159754A2 (enExample)
ZA (1) ZA201306944B (enExample)

Families Citing this family (233)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9365901B2 (en) 2008-11-07 2016-06-14 Adaptive Biotechnologies Corp. Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia
US9506119B2 (en) 2008-11-07 2016-11-29 Adaptive Biotechnologies Corp. Method of sequence determination using sequence tags
US8748103B2 (en) 2008-11-07 2014-06-10 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
US9528160B2 (en) 2008-11-07 2016-12-27 Adaptive Biotechnolgies Corp. Rare clonotypes and uses thereof
EP3699296A1 (en) 2008-11-07 2020-08-26 Adaptive Biotechnologies Corporation Methods of monitoring conditions by sequence analysis
HUE029424T2 (en) 2009-01-15 2017-02-28 Adaptive Biotechnologies Corp Adaptive immunity profiling and a method for producing monoclonal antibodies
RU2014144463A (ru) 2009-06-25 2015-06-20 Фред Хатчинсон Кансэр Рисёч Сентер Способ измерения адаптивного иммунитета
US8835358B2 (en) 2009-12-15 2014-09-16 Cellular Research, Inc. Digital counting of individual molecules by stochastic attachment of diverse labels
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP4108671B1 (en) 2010-10-01 2024-11-20 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
ES2746233T3 (es) 2011-05-24 2020-03-05 Biontech Rna Pharmaceuticals Gmbh Vacunas individualizadas para el cáncer
US10385475B2 (en) 2011-09-12 2019-08-20 Adaptive Biotechnologies Corp. Random array sequencing of low-complexity libraries
AU2012325791B2 (en) 2011-10-21 2018-04-05 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
EP2788509B1 (en) 2011-12-09 2018-07-11 Adaptive Biotechnologies Corporation Diagnosis of lymphoid malignancies and minimal residual disease detection
US9499865B2 (en) 2011-12-13 2016-11-22 Adaptive Biotechnologies Corp. Detection and measurement of tissue-infiltrating lymphocytes
MX2014007233A (es) 2011-12-16 2015-02-04 Moderna Therapeutics Inc Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados.
JP6375230B2 (ja) 2012-02-27 2018-08-15 セルラー リサーチ， インコーポレイテッド 分子計数のための組成物およびキット
ES2662128T3 (es) 2012-03-05 2018-04-05 Adaptive Biotechnologies Corporation Determinación de cadenas de receptor inmunitario emparejadas a partir de la frecuencia de subunidades coincidentes
WO2013151663A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
PT2831276T (pt) 2012-05-08 2016-07-26 Adaptive Biotechnologies Corp Composições e método para medição e calibração do viés de amplificação em reações pcr multiplex
MX364370B (es) * 2012-07-12 2019-04-24 Persimmune Inc Vacunas contra el cancer personalizadas y terapias de celulas inmunes adoptivas.
EP2885419A4 (en) 2012-08-14 2016-05-25 Moderna Therapeutics Inc ENZYMES AND POLYMERASES FOR RNA SYNTHESIS
EP2901341B1 (en) * 2012-09-28 2019-04-10 The University of Connecticut Identification of tumor-protective epitopes for the treatment of cancers
ES2660027T3 (es) 2012-10-01 2018-03-20 Adaptive Biotechnologies Corporation Evaluación de la inmunocompetencia por la diversidad de los receptores de inmunidad adaptativa y caracterización de la clonalidad
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
CA2892391C (en) * 2012-11-28 2023-10-17 Biontech Rna Pharmaceuticals Gmbh Individualized vaccines for cancer
WO2014093186A1 (en) * 2012-12-12 2014-06-19 Garvin Alex M Non-invasive detection of colorectal neoplasia using circular consensus sequencing
EP4414990A3 (en) 2013-01-17 2024-11-06 Personalis, Inc. Methods and systems for genetic analysis
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
SG11201506991VA (en) * 2013-03-15 2015-10-29 Adaptive Biotechnologies Corp Uniquely tagged rearranged adaptive immune receptor genes in a complex gene set
JP6702855B2 (ja) 2013-04-07 2020-06-03 ザ・ブロード・インスティテュート・インコーポレイテッド 個別化された新生物ワクチンの組成物及び方法
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
US9708657B2 (en) 2013-07-01 2017-07-18 Adaptive Biotechnologies Corp. Method for generating clonotype profiles using sequence tags
US20160186260A1 (en) * 2013-07-26 2016-06-30 Sequenta, Llc Cancer vaccination with antigen evolution
EP3480321B8 (en) 2013-08-28 2021-03-10 Becton, Dickinson and Company Massively parallel single cell analysis
EP4567682A3 (en) 2013-08-30 2025-09-03 Personalis, Inc. Methods for genomic analysis
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
GB2535066A (en) 2013-10-03 2016-08-10 Personalis Inc Methods for analyzing genotypes
CN105745528A (zh) 2013-10-07 2016-07-06 赛卢拉研究公司 用于以数字方式对阵列上的特征进行计数的方法和系统
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
ES2693217T3 (es) 2013-12-02 2018-12-10 Personal Genome Diagnostics Inc. Método para evaluar variantes minoritarias en una muestra
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
EP4052724A1 (en) * 2013-12-06 2022-09-07 The Broad Institute Inc. Formulations for neoplasia vaccines
BR112016014410A2 (pt) * 2013-12-20 2018-02-20 The Broad Institute Inc. terapia de combinação com vacina de neoantígeno
WO2015134787A2 (en) 2014-03-05 2015-09-11 Adaptive Biotechnologies Corporation Methods using randomer-containing synthetic molecules
US10066265B2 (en) 2014-04-01 2018-09-04 Adaptive Biotechnologies Corp. Determining antigen-specific t-cells
EP3132059B1 (en) 2014-04-17 2020-01-08 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
PT3134131T (pt) 2014-04-23 2022-03-24 Modernatx Inc Vacinas de ácidos nucleicos
US10017759B2 (en) * 2014-06-26 2018-07-10 Illumina, Inc. Library preparation of tagged nucleic acid
CN107076762B (zh) 2014-09-10 2021-09-10 豪夫迈·罗氏有限公司 免疫原性突变体肽筛选平台
US11338026B2 (en) 2014-09-10 2022-05-24 The University Of Connecticut Identification of immunologically protective neo-epitopes for the treatment of cancers
JP6599450B2 (ja) 2014-10-02 2019-10-30 アメリカ合衆国 がん特異的突然変異に対し抗原特異性を有するｔ細胞を単離する方法
EP3715455A1 (en) 2014-10-29 2020-09-30 Adaptive Biotechnologies Corp. Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples
EP3212808B1 (en) 2014-10-30 2022-03-02 Personalis, Inc. Methods for using mosaicism in nucleic acids sampled distal to their origin
US10246701B2 (en) 2014-11-14 2019-04-02 Adaptive Biotechnologies Corp. Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture
US11066705B2 (en) 2014-11-25 2021-07-20 Adaptive Biotechnologies Corporation Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing
EP3234130B1 (en) 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
WO2016128060A1 (en) * 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
CN107250379B (zh) * 2015-02-19 2021-12-28 贝克顿迪金森公司 结合蛋白质组信息和基因组信息的高通量单细胞分析
WO2016138122A1 (en) 2015-02-24 2016-09-01 Adaptive Biotechnologies Corp. Methods for diagnosing infectious disease and determining hla status using immune repertoire sequencing
MX2017010944A (es) 2015-02-26 2018-07-06 Sio2 Medical Products Inc Recipiente de polimero de cicloolefina con un revestimiento resistente a arañazos y antiestatico.
CN107208158B (zh) 2015-02-27 2022-01-28 贝克顿迪金森公司 空间上可寻址的分子条形编码
EP4180535A1 (en) 2015-03-30 2023-05-17 Becton, Dickinson and Company Methods and compositions for combinatorial barcoding
US11041202B2 (en) 2015-04-01 2021-06-22 Adaptive Biotechnologies Corporation Method of identifying human compatible T cell receptors specific for an antigenic target
WO2016172373A1 (en) 2015-04-23 2016-10-27 Cellular Research, Inc. Methods and compositions for whole transcriptome amplification
WO2016174085A1 (en) * 2015-04-27 2016-11-03 Cancer Research Technology Limited Method for treating cancer
WO2016180467A1 (en) 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination
SG10201912485PA (en) * 2015-05-13 2020-02-27 Agenus Inc Vaccines for treatment and prevention of cancer
BR112017024797A2 (pt) 2015-05-20 2018-08-07 The Broad Institute Inc. neoantígenos partilhados
US11124823B2 (en) 2015-06-01 2021-09-21 Becton, Dickinson And Company Methods for RNA quantification
TW202241500A (zh) * 2015-06-09 2022-11-01 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
EP3328394A4 (en) * 2015-07-30 2019-03-13 ModernaTX, Inc. CONCATEMEE peptide epitope RNAs
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
JP6940484B2 (ja) 2015-09-11 2021-09-29 セルラー リサーチ， インコーポレイテッド ライブラリー正規化のための方法および組成物
JP6990176B2 (ja) 2015-10-05 2022-02-03 モデルナティエックス インコーポレイテッド メッセンジャーリボ核酸薬物の治療投与のための方法
KR102770755B1 (ko) * 2015-10-12 2025-02-21 난토믹스, 엘엘씨 바이러스 네오에피토프 및 이의 용도
EP3362103B1 (en) 2015-10-12 2025-01-22 Nantomics, LLC Compositions and methods for viral cancer neoepitopes
US20180318409A1 (en) * 2015-10-22 2018-11-08 Modernatx, Inc. Cancer vaccines
SG11201804957VA (en) 2015-12-16 2018-07-30 Gritstone Oncology Inc Neoantigen identification, manufacture, and use
CN105349533A (zh) * 2015-12-21 2016-02-24 生工生物工程（上海）股份有限公司 构建链特异性转录组文库的方法
EP3400005A1 (en) * 2016-01-08 2018-11-14 Vaccibody AS Neoepitope rna cancer vaccine
CA3008437A1 (en) * 2016-01-08 2017-07-13 Vaccibody As Therapeutic anticancer neoepitope vaccine
AU2017281126A1 (en) 2016-03-24 2018-10-04 Nant Holdings Ip, Llc Sequence arrangements and sequences for neoepitope presentation
KR20180129899A (ko) 2016-03-31 2018-12-05 네온 테라퓨틱스, 인크. 신생항원 및 이것의 사용 방법
US20190346442A1 (en) 2016-04-18 2019-11-14 The Broad Institute, Inc. Improved hla epitope prediction
US20190343942A1 (en) * 2016-04-22 2019-11-14 Curevac Ag Rna encoding a tumor antigen
WO2017192387A1 (en) 2016-05-02 2017-11-09 Cellular Research, Inc. Accurate molecular barcoding
CN109328070A (zh) * 2016-05-04 2019-02-12 免疫疫苗技术有限公司 包含两亲化合物、新抗原和疏水载体的疫苗组合物及其使用方法
WO2017194170A1 (en) 2016-05-13 2017-11-16 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
US10301677B2 (en) 2016-05-25 2019-05-28 Cellular Research, Inc. Normalization of nucleic acid libraries
CN109074430B (zh) 2016-05-26 2022-03-29 贝克顿迪金森公司 分子标记计数调整方法
KR20200138418A (ko) * 2016-05-27 2020-12-09 이투빅스 코포레이션 네오에피토프 백신 조성물 및 이의 사용 방법
US11299783B2 (en) 2016-05-27 2022-04-12 Personalis, Inc. Methods and systems for genetic analysis
US10202641B2 (en) 2016-05-31 2019-02-12 Cellular Research, Inc. Error correction in amplification of samples
US10640763B2 (en) 2016-05-31 2020-05-05 Cellular Research, Inc. Molecular indexing of internal sequences
US10821163B2 (en) * 2016-07-13 2020-11-03 Vaximm Ag Process for the production of a DNA vaccine for cancer immunotherapy
HUE056660T2 (hu) * 2016-07-20 2022-03-28 BioNTech SE A neoepitópok mint betegségspecifikus célpontok kiválasztása a fokozott hatékonyságú terápia számára
US10428325B1 (en) 2016-09-21 2019-10-01 Adaptive Biotechnologies Corporation Identification of antigen-specific B cell receptors
BR112019005900A2 (pt) 2016-09-26 2019-06-11 Cellular Research, Inc. medição de expressão de proteínas usando reagentes com sequências de oligonucleotídeos com código de barras
US11608497B2 (en) 2016-11-08 2023-03-21 Becton, Dickinson And Company Methods for cell label classification
SG11201903139SA (en) 2016-11-08 2019-05-30 Cellular Res Inc Methods for expression profile classification
US20190321481A1 (en) 2016-11-11 2019-10-24 Nantbio, Inc. Immunomodulatory compositions, processes for making the same, and methods for inhibiting cytokine storms
CN108090325B (zh) * 2016-11-23 2022-01-25 中国科学院昆明动物研究所 一种应用β-稳定性分析单细胞测序数据的方法
EP3568234B1 (en) 2017-01-13 2023-09-06 Cellular Research, Inc. Hydrophilic coating of fluidic channels
US20190369096A1 (en) * 2017-01-13 2019-12-05 Nantbio, Inc. Validation of neoepitope-based treatment
US12331359B2 (en) * 2017-01-18 2025-06-17 Michael Laessig Neoantigens and uses thereof for treating cancer
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
AU2018214556A1 (en) * 2017-02-01 2019-08-15 Modernatx, Inc. Immunomodulatory therapeutic mRNA compositions encoding activating oncogene mutation peptides
JP7731656B2 (ja) * 2017-02-01 2025-09-01 モデルナティエックス インコーポレイテッド Ｒｎａ癌ワクチン
CN110382708A (zh) 2017-02-01 2019-10-25 赛卢拉研究公司 使用阻断性寡核苷酸进行选择性扩增
EP4287191A3 (en) 2017-02-12 2024-03-06 BioNTech US Inc. Hla-based methods and compositions and uses thereof
CN118161496A (zh) 2017-03-31 2024-06-11 小利兰·斯坦福大学托管委员会 通过抑制或调节t细胞受体信号传导来治疗t细胞耗竭的方法
CN118370809A (zh) 2017-04-03 2024-07-23 百欧恩泰美国公司 蛋白质抗原及其用途
US11905525B2 (en) 2017-04-05 2024-02-20 Modernatx, Inc. Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
EP3615675A4 (en) 2017-04-24 2021-03-03 Nantcell, Inc. TARGETED NEO-EPITOPIC VECTORS AND ASSOCIATED PROCESSES
CA3062591A1 (en) 2017-05-08 2018-11-15 Gritstone Oncology, Inc. Alphavirus neoantigen vectors
EP3621629A4 (en) * 2017-05-11 2021-03-17 Theralase Biotech Inc. VACCINE WITH CANCER CELLS INACTIVATED BY PHOTODYNAMIC TREATMENT WITH METAL-BASED COORDINATION COMPLEX AND IMMUNOTHERAPY PROCEDURES WITH IT
EP3933408A1 (en) 2017-05-30 2022-01-05 Nant Holdings IP LLC Circulating tumor cell enrichment using neoepitopes
CA3059559A1 (en) 2017-06-05 2018-12-13 Becton, Dickinson And Company Sample indexing for single cells
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
AU2018287159B2 (en) 2017-06-21 2025-01-16 Transgene Personalized vaccine
WO2019005764A1 (en) 2017-06-27 2019-01-03 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center MHC-I GENOTYPE LIMITING THE ONCOGEN MUTATIONAL LANDSCAPE
CN111093699A (zh) * 2017-07-12 2020-05-01 Nouscom股份公司 用于治疗癌症的新抗原疫苗组合物
US10636512B2 (en) 2017-07-14 2020-04-28 Cofactor Genomics, Inc. Immuno-oncology applications using next generation sequencing
EP4576103A3 (en) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigen identification using hotspots
KR20200090855A (ko) 2017-11-22 2020-07-29 그릿스톤 온콜로지, 인코포레이티드 신생항원에 대한 접합 에피토프 제시 감소
US20200354730A1 (en) * 2017-11-27 2020-11-12 Nantcell, Inc. Improved Yeast Polytope Vaccine Compositions And Methods
US11254980B1 (en) 2017-11-29 2022-02-22 Adaptive Biotechnologies Corporation Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements
TWI727232B (zh) * 2017-12-01 2021-05-11 大陸商上海桀蒙生物技術有限公司 個人化癌症疫苗的製備方法
TW201930340A (zh) 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
US11972841B2 (en) 2017-12-18 2024-04-30 Personal Genome Diagnostics Inc. Machine learning system and method for somatic mutation discovery
CN111492068B (zh) 2017-12-19 2025-03-21 贝克顿迪金森公司 与寡核苷酸相关联的颗粒
CN111818943B (zh) 2018-01-04 2024-09-03 伊科尼克治疗公司 抗组织因子抗体、抗体-药物缀合物及相关方法
JP7437310B2 (ja) * 2018-03-14 2024-02-22 コーニンクレッカ フィリップス エヌ ヴェ Ｒｎａシーケンシングデータの転写発現レベルを解釈するために局所的なユニークな特徴を使用するシステム及び方法
AU2019244115A1 (en) * 2018-03-30 2020-11-19 Juno Diagnostics, Inc. Deep learning-based methods, devices, and systems for prenatal testing
TW202012430A (zh) 2018-04-26 2020-04-01 美商艾吉納斯公司 熱休克蛋白質－結合之胜肽組成物及其使用方法
CN112243461B (zh) 2018-05-03 2024-07-12 贝克顿迪金森公司 在相对的转录物末端进行分子条形码化
EP3788171B1 (en) 2018-05-03 2023-04-05 Becton, Dickinson and Company High throughput multiomics sample analysis
IL259392A (en) 2018-05-15 2018-08-01 Yeda Res & Dev Vaccination with cancer neoantigens
KR20210018321A (ko) * 2018-05-25 2021-02-17 더 위스타 인스티튜트 종양 특이적 신생항원 및 이를 사용하는 방법
CN108897986B (zh) * 2018-05-29 2020-11-27 中南大学 一种基于蛋白质信息的基因组序列拼接方法
US10801064B2 (en) 2018-05-31 2020-10-13 Personalis, Inc. Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples
US11814750B2 (en) 2018-05-31 2023-11-14 Personalis, Inc. Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples
BR112020025764A2 (pt) 2018-06-19 2021-05-11 Biontech Us Inc. neoantígenos e usos dos mesmos
CA3104673A1 (en) * 2018-06-27 2020-01-02 Modernatx, Inc. Personalized cancer vaccine epitope selection
WO2020020444A1 (en) * 2018-07-24 2020-01-30 Biontech Rna Pharmaceuticals Gmbh Individualized vaccines for cancer
US12391736B2 (en) 2018-07-26 2025-08-19 Curevac Netherlands B.V. Off-the-shelf cancer vaccines
SG11202101965QA (en) 2018-09-27 2021-04-29 Vaccibody As Method for selecting neoepitopes
CN112805389B (zh) 2018-10-01 2024-08-06 贝克顿迪金森公司 确定5’转录物序列
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
CN114681600A (zh) * 2018-10-19 2022-07-01 杭州纽安津生物科技有限公司 通用性多肽疫苗及其在制备治疗/预防胰腺癌药物中的应用
EP3876947A4 (en) * 2018-11-07 2022-08-31 ModernaTX, Inc. RNA CANCER VACCINES
WO2020097315A1 (en) 2018-11-08 2020-05-14 Cellular Research, Inc. Whole transcriptome analysis of single cells using random priming
CA3114265A1 (en) * 2018-11-15 2020-05-22 Nouscom Ag Selection of cancer mutations for generation of a personalized cancer vaccine
WO2020123384A1 (en) 2018-12-13 2020-06-18 Cellular Research, Inc. Selective extension in single cell whole transcriptome analysis
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
AU2019404547B2 (en) * 2018-12-21 2025-01-30 Biontech Us Inc. Method and systems for prediction of HLA class II-specific epitopes and characterization of CD4+ T cells
GB201821205D0 (en) * 2018-12-24 2019-02-06 Tcer Ab Immunotherapy
GB201821207D0 (en) 2018-12-24 2019-02-06 Tcer Ab Immunotherapy therapy
EP3909062A4 (en) * 2019-01-08 2022-10-05 Caris MPI, Inc. GENOMIC PROFILING SIMILARITY
WO2020150152A1 (en) * 2019-01-14 2020-07-23 Genentech, Inc. Methods of treating cancer with a pd-1 axis binding antagonist and an rna vaccine
US11371076B2 (en) 2019-01-16 2022-06-28 Becton, Dickinson And Company Polymerase chain reaction normalization through primer titration
ES2945227T3 (es) 2019-01-23 2023-06-29 Becton Dickinson Co Oligonucleótidos asociados con anticuerpos
JP2022519649A (ja) 2019-02-08 2022-03-24 ジェネンテック， インコーポレイテッド がんの診断および治療方法
US12071617B2 (en) 2019-02-14 2024-08-27 Becton, Dickinson And Company Hybrid targeted and whole transcriptome amplification
EP3923979A1 (en) * 2019-02-15 2021-12-22 Rjan Holding AB Autologous cancer tumour associated extrachromosomal circular dna for use as a therapeutic vaccine
AU2020232971A1 (en) * 2019-03-01 2021-09-23 Scott R. BURKHOLZ Design, manufacture, and use of personalized cancer vaccines
US20220154180A1 (en) 2019-03-13 2022-05-19 Toyobo Co., Ltd. Production and amplification of nucleic acids
WO2020214642A1 (en) 2019-04-19 2020-10-22 Becton, Dickinson And Company Methods of associating phenotypical data and single cell sequencing data
JP7457733B2 (ja) 2019-05-30 2024-03-28 グリットストーン バイオ インコーポレイテッド 改変アデノウイルス
CN112011833B (zh) * 2019-05-30 2024-04-26 上海桀蒙生物技术有限公司 筛选和分离肿瘤新生抗原的方法
CN120099137A (zh) 2019-07-22 2025-06-06 贝克顿迪金森公司 单细胞染色质免疫沉淀测序测定
CN110277135B (zh) * 2019-08-10 2021-06-01 杭州新范式生物医药科技有限公司 一种基于预期疗效选择个体化肿瘤新抗原的方法和系统
EP4031562A4 (en) * 2019-09-20 2023-11-01 University of Florida Research Foundation, Incorporated DETECTION OF ANTIBODIES AGAINST RAN PROTEINS FROM SERUM AND TISSUE LYSATES
TWI793451B (zh) * 2019-09-20 2023-02-21 納維再生科技股份有限公司 個人化癌症免疫治療
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
EP4055610A4 (en) 2019-11-05 2023-11-29 Personalis, Inc. ESTIMATION OF TUMOR PURITY FROM SINGLE SAMPLES
ES2987640T3 (es) 2019-11-08 2024-11-15 Becton Dickinson Co Uso de cebado aleatorio para obtener información de V(D)J de longitud completa para la secuenciación del repertorio inmunitario
CN112795647B (zh) * 2019-11-14 2022-08-16 北京肿瘤医院(北京大学肿瘤医院) 一种肿瘤标志物及其应用
US11845799B2 (en) 2019-12-13 2023-12-19 Genentech, Inc. Anti-Ly6G6D antibodies and methods of use
US11649497B2 (en) 2020-01-13 2023-05-16 Becton, Dickinson And Company Methods and compositions for quantitation of proteins and RNA
CN115335520A (zh) 2020-01-29 2022-11-11 贝克顿迪金森公司 用于通过测序对单细胞进行空间映射的条形码化的孔
US12153043B2 (en) 2020-02-25 2024-11-26 Becton, Dickinson And Company Bi-specific probes to enable the use of single-cell samples as single color compensation control
US20230114434A1 (en) 2020-03-13 2023-04-13 Codiak Biosciences, Inc. Extracellular vesicles for treating neurological disorders
EP4121450A2 (en) 2020-03-20 2023-01-25 Codiak BioSciences, Inc. Extracellular vesicles for therapy
US11920202B2 (en) 2020-04-09 2024-03-05 University Of Connecticut Unbiased identification of tumor rejection mediating neoepitopes
US11661625B2 (en) 2020-05-14 2023-05-30 Becton, Dickinson And Company Primers for immune repertoire profiling
CN116249774A (zh) 2020-05-26 2023-06-09 迪奥尼斯治疗公司 核酸人工微型蛋白质组文库
EP4407030B1 (en) 2020-06-02 2025-12-17 Becton, Dickinson and Company Oligonucleotides and beads for 5 prime gene expression assay
US11932901B2 (en) 2020-07-13 2024-03-19 Becton, Dickinson And Company Target enrichment using nucleic acid probes for scRNAseq
WO2022026909A1 (en) 2020-07-31 2022-02-03 Becton, Dickinson And Company Single cell assay for transposase-accessible chromatin
CA3187258A1 (en) 2020-08-06 2022-02-10 Karin Jooss Multiepitope vaccine cassettes
EP4196612A1 (en) 2020-08-12 2023-06-21 Genentech, Inc. Diagnostic and therapeutic methods for cancer
GB2613718A (en) * 2020-08-31 2023-06-14 World Biotech Regenerative Medical Group Ltd Personalized immunogenic compositions and methods for producing and using same
US20240082389A1 (en) 2020-09-23 2024-03-14 Lonza Sales Ag Methods of producing extracellular vesicles
CN116635533A (zh) 2020-11-20 2023-08-22 贝克顿迪金森公司 高表达的蛋白和低表达的蛋白的谱分析
US11161892B1 (en) 2020-12-07 2021-11-02 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
EP4259206A4 (en) 2020-12-14 2025-07-09 Biontech Us Inc TISSUE-SPECIFIC ANTIGENS FOR CANCER IMMUNOTHERAPY
US12392771B2 (en) 2020-12-15 2025-08-19 Becton, Dickinson And Company Single cell secretome analysis
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
WO2023025404A1 (en) 2021-08-24 2023-03-02 BioNTech SE In vitro transcription technologies
US12297508B2 (en) 2021-10-05 2025-05-13 Personalis, Inc. Customized assays for personalized cancer monitoring
WO2023076733A1 (en) 2021-11-01 2023-05-04 Dana-Farber Cancer Institute, Inc. Biologically selected nucleic acid artificial mini-proteome libraries
JPWO2023085232A1 (enExample) 2021-11-10 2023-05-19
CN114181287B (zh) * 2021-12-10 2023-09-19 商丘美兰生物工程有限公司 一种dna病毒疫苗的制备方法
CN114410778B (zh) * 2021-12-29 2024-03-19 中南大学湘雅医院 Pf543在制备pd-l1/pd-1单抗肿瘤免疫治疗药物中的应用
CN114350800B (zh) * 2021-12-29 2024-03-19 中南大学湘雅医院 Sphk1在制备pd-l1/pd-1单抗肿瘤免疫治疗药物中的应用
KR20230130804A (ko) * 2022-03-04 2023-09-12 (주)큐리진 순환종양세포 검출을 위한 아데노바이러스 5/3 형
EP4253550A1 (en) 2022-04-01 2023-10-04 GenCC GmbH 6 Co. KG Method for the manufacture of a viral system, a vector system or any transport system for cancer-specific crispr complexes
WO2023209068A1 (en) 2022-04-28 2023-11-02 Carbocalyx Gmbh Personalized anticancer vaccine comprising glycoengineered tumour cells or tumour cell fragments
WO2024015892A1 (en) 2022-07-13 2024-01-18 The Broad Institute, Inc. Hla-ii immunopeptidome methods and systems for antigen discovery
WO2024063788A1 (en) * 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of malaria antigens and related methods
EP4590330A1 (en) * 2022-09-23 2025-07-30 BioNTech SE Compositions for delivery of liver stage antigens and related methods
WO2024083345A1 (en) 2022-10-21 2024-04-25 BioNTech SE Methods and uses associated with liquid compositions
EP4656735A1 (en) 2023-01-26 2025-12-03 Toyobo Co., Ltd. Inibhition of reverse transcription derived from ribosomal rna
WO2025024337A1 (en) * 2023-07-24 2025-01-30 BioNTech SE Compositions for delivery of plasmodium antigens and related methods
WO2025064850A1 (en) * 2023-09-22 2025-03-27 BioNTech SE Rna constructs with n-terminal degrons to enhance an immune response
WO2025097055A2 (en) 2023-11-02 2025-05-08 The Broad Institute, Inc. Compositions and methods of use of t cells in immunotherapy
WO2025146078A1 (en) * 2024-01-04 2025-07-10 Everest Medicines (China) Co., Ltd. Cancer vaccines and uses thereof
WO2025191449A1 (en) 2024-03-11 2025-09-18 Instadeep Ltd Systems and methods for machine learning-based genome annotation
WO2025202937A1 (en) 2024-03-26 2025-10-02 BioNTech SE Cancer vaccines
WO2025207807A1 (en) * 2024-03-27 2025-10-02 The University Of Florida Research Foundation, Inc. Ctc rna-loaded nanoparticles and use thereof for the treatment of cancer
CN119049567B (zh) * 2024-08-08 2025-07-22 笙源生命科技(安吉)有限公司 一种基于单细胞测序区分嵌合体动物模型中异种杂交样本遗传物质和细胞物种来源的方法

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
EP0871747A1 (en) 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunostimulation mediated by gene-modified dendritic cells
AU2734397A (en) * 1996-04-19 1997-11-12 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Mutated ras peptides for generation of cd8+ cytotoxic t lymphocytes
PT900380E (pt) 1996-04-26 2003-12-31 Univ Leiden Metodos para seleccionar e produzir epitopos peptidicos de celulas t e vacinas que incorporam os referidos epitopos seleccionados
CN1138533C (zh) 1996-09-13 2004-02-18 利普森有限公司 脂质体
CA2267157C (en) * 1996-10-11 2005-05-31 The Regents Of The University Of California Cancer immunotherapy using tumor cells combined with mixed lymphocytes
EP0839912A1 (en) 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
US6074645A (en) 1996-11-12 2000-06-13 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
AU743066B2 (en) 1997-11-06 2002-01-17 Roche Diagnostics Gmbh Tumor-specific antigens, methods for their production and their use for immunization and diagnosis
WO1999034014A2 (en) 1997-12-23 1999-07-08 Roche Diagnostics Gmbh A method for the determination of a nucleic acid
WO1999034015A2 (en) * 1997-12-24 1999-07-08 Imperial Cancer Research Technology Limited Polymorphisms within the rsk-3 gene related to cancer and methods of diagnosis, prognosis, and treatment
US6432925B1 (en) 1998-04-16 2002-08-13 John Wayne Cancer Institute RNA cancer vaccine and methods for its use
AU6289699A (en) 1998-10-05 2000-04-26 Genzyme Corporation Genes differentially expressed in cancer cells to design cancer vaccines
CA2374237A1 (en) 1999-05-06 2000-11-16 Wake Forest University Compositions and methods for identifying antigens which elicit an immune response
CA2384987A1 (en) 1999-09-16 2001-03-22 Zycos Inc. Nucleic acids encoding polyepitope polypeptides
CA2388045C (en) * 1999-10-20 2014-02-11 Tzyy-Choou Wu Nucleic acid immunogenic compositions encoding hsp-antigen chimera
WO2001047959A2 (en) 1999-11-30 2001-07-05 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
DE60035523T2 (de) 1999-12-28 2008-03-20 Pharmexa Inc., San Diego Optimierte minigene und dadurch kodierte peptide
AU2001275294A1 (en) 2000-06-07 2001-12-17 Biosynexus Incorporated. Immunostimulatory RNA/DNA hybrid molecules
AU2001278117A1 (en) 2000-08-03 2002-02-18 Johns Hopkins University Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
US6472176B2 (en) 2000-12-14 2002-10-29 Genvec, Inc. Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof
EP1903054A3 (de) 2001-06-05 2008-07-23 CureVac GmbH Stabilisierte mRNA mit erhöhtem G/C-Gehalt und optimierter Codon Usage für die Gentherapie
AUPR593101A0 (en) * 2001-06-26 2001-07-19 Council Of The Queensland Institute Of Medical Research, The Cytomegalovirus t cell epitopes
NZ533237A (en) 2001-11-26 2005-11-25 Univ Queensland Flavivirus vaccine delivery system
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
AU2003235707A1 (en) 2002-01-18 2003-07-30 Curevac Gmbh Immunogenic preparations and vaccines on the basis of mrna
AUPS054702A0 (en) 2002-02-14 2002-03-07 Immunaid Pty Ltd Cancer therapy
WO2003070162A2 (en) * 2002-02-19 2003-08-28 Genzyme Corporation Par-3 compounds for therapy and diagnosis and methods for using same
AU2003218181A1 (en) * 2002-03-15 2003-09-29 Multicell Immunotherapeutics, Inc. Immunostimulatory double stranded RNA and methods of inducing, enhancing or modulating the immune response
PT1512014E (pt) 2002-06-13 2009-11-10 Merck Patent Gmbh Método de identificação de alo-antigénios e sua utilização para terapia de cancro e transplante
DE10229872A1 (de) 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
DE10335833A1 (de) * 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
IL158140A0 (en) 2003-09-25 2004-03-28 Hadasit Med Res Service Multiepitope polypeptides for cancer immunotherapy
DE10344799A1 (de) 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
EP1673069B1 (en) 2003-10-15 2016-10-12 SynCore Biotechnology CO., LTD Cationic liposomes comprising an active drug for use in treatment of cancer
CN1898569A (zh) 2003-10-24 2007-01-17 伊缪因艾德有限公司 治疗方法
EP1589030A1 (en) * 2004-04-14 2005-10-26 Friedrich-Alexander-Universität Erlangen-Nürnberg Bob-1 specific T cells and methods to use
US7303881B2 (en) 2004-04-30 2007-12-04 Pds Biotechnology Corporation Antigen delivery compositions and methods of use
DE102004023187A1 (de) 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
DE102004035227A1 (de) 2004-07-21 2006-02-16 Curevac Gmbh mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
DE102004057303A1 (de) 2004-11-26 2006-06-01 Merck Patent Gmbh Stabile Kristallmodifikationen von DOTAP Chlorid
US8703142B2 (en) 2004-12-29 2014-04-22 Mannkind Corporation Methods to bypass CD4+ cells in the induction of an immune response
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
PL1907424T3 (pl) 2005-07-01 2015-12-31 Squibb & Sons Llc Ludzkie monoklonalne przeciwciała wobec liganda zaprogramowanej śmierci 1 (PD-L1)
LT2578685T (lt) 2005-08-23 2019-06-10 The Trustees Of The University Of Pennsylvania Rnr, apimančios modifikuotus nukleozidus ir jų panaudojimo būdai
DE102005041616B4 (de) 2005-09-01 2011-03-17 Johannes-Gutenberg-Universität Mainz Melanom-assoziierte MHC Klasse I assoziierte Oligopeptide und für diese kodierende Polynukleotide und deren Verwendungen
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
EP1994181A4 (en) 2006-02-27 2010-05-19 Univ Arizona IDENTIFICATION AND USE OF NOVOPEPTIDES FOR THE TREATMENT OF CANCER
CA2647280A1 (en) 2006-03-13 2007-09-20 Veridex, Llc Propagation of primary cells
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
US20090304711A1 (en) 2006-09-20 2009-12-10 Drew Pardoll Combinatorial Therapy of Cancer and Infectious Diseases with Anti-B7-H1 Antibodies
DE102006060824B4 (de) 2006-12-21 2011-06-01 Johannes-Gutenberg-Universität Mainz Nachweis von individuellen T-Zell-Reaktionsmustern gegen Tumor-assoziierte Antigene (TAA) in Tumorpatienten als Basis für die individuelle therapeutische Vakzinierung von Patienten
SI2079760T1 (sl) 2006-12-27 2016-11-30 Emory University Sestavki in metode za zdravljenje okužb
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
US8140270B2 (en) 2007-03-22 2012-03-20 National Center For Genome Resources Methods and systems for medical sequencing analysis
US8354509B2 (en) 2007-06-18 2013-01-15 Msd Oss B.V. Antibodies to human programmed death receptor PD-1
WO2009046738A1 (en) * 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
UA105764C2 (uk) 2008-03-24 2014-06-25 4 Сц Аг Заміщені імідазохіноліни
CA2721366C (en) 2008-04-17 2017-06-06 Elizabeth Ann Vasievich Stimulation of an immune response by enantiomers of cationic lipids
JP5268444B2 (ja) * 2008-06-23 2013-08-21 株式会社日立ハイテクノロジーズ 単分子リアルタイムシーケンス装置，核酸分析装置及び単分子リアルタイムシーケンス方法
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
WO2010037395A2 (en) 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
US20110195090A1 (en) 2008-10-11 2011-08-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Method of making a vaccine
HUE028582T2 (en) 2008-11-28 2016-12-28 Univ Emory Method for determining the efficacy of PD-1 antagonists
DE102008061522A1 (de) 2008-12-10 2010-06-17 Biontech Ag Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
KR20140119197A (ko) 2009-07-31 2014-10-08 에트리스 게엠베하 단백질 발현을 위한 비변형된 뉴클레오티드 및 변형된 뉴클레오티드의 조합을 가진 ｒｎａ
WO2013040142A2 (en) 2011-09-16 2013-03-21 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
HUE049886T2 (hu) 2010-05-14 2020-10-28 Massachusetts Gen Hospital Tumorspecifikus neoantigéneket tartalmazó készítmények, tumorok kezelésében történõ alkalmazásra
EP4108671B1 (en) 2010-10-01 2024-11-20 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
DE102011102734A1 (de) 2011-05-20 2012-11-22 WMF Württembergische Metallwarenfabrik Aktiengesellschaft Vorrichtung zum Aufschäumen von Milch, Getränkebereiter mit dieser Vorrichtung und Verfahren zum Aufschäumen von Milch
WO2012159643A1 (en) 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
EP3892295B1 (en) 2011-05-24 2023-04-26 BioNTech SE Individualized vaccines for cancer
ES2746233T3 (es) 2011-05-24 2020-03-05 Biontech Rna Pharmaceuticals Gmbh Vacunas individualizadas para el cáncer
ES2911677T3 (es) 2011-10-03 2022-05-20 Modernatx Inc Nucleósidos, nucleótidos y ácidos nucleicos modificados, y sus usos
MX2014007233A (es) 2011-12-16 2015-02-04 Moderna Therapeutics Inc Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados.
US20150030576A1 (en) 2012-01-10 2015-01-29 Moderna Therapeutics, Inc. Methods and compositions for targeting agents into and across the blood-brain barrier
EP2817322B1 (en) 2012-02-20 2016-04-20 Universita' degli Studi di Milano Homo- and heterodimeric smac mimetic compounds as apoptosis inducers
US20130255281A1 (en) 2012-03-29 2013-10-03 General Electric Company System and method for cooling electrical components
WO2013151663A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
MX364370B (es) 2012-07-12 2019-04-24 Persimmune Inc Vacunas contra el cancer personalizadas y terapias de celulas inmunes adoptivas.
WO2014071219A1 (en) 2012-11-01 2014-05-08 Factor Bioscience Inc. Methods and products for expressing proteins in cells
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
EP2931319B1 (en) 2012-12-13 2019-08-21 ModernaTX, Inc. Modified nucleic acid molecules and uses thereof
US20160022840A1 (en) 2013-03-09 2016-01-28 Moderna Therapeutics, Inc. Heterologous untranslated regions for mrna
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
WO2014160243A1 (en) 2013-03-14 2014-10-02 The Trustees Of The University Of Pennsylvania Purification and purity assessment of rna molecules synthesized with modified nucleosides
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
WO2014144039A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Characterization of mrna molecules
WO2014152027A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Manufacturing methods for production of rna transcripts
EP2971161B1 (en) 2013-03-15 2018-12-26 ModernaTX, Inc. Ribonucleic acid purification
US10077439B2 (en) 2013-03-15 2018-09-18 Modernatx, Inc. Removal of DNA fragments in mRNA production process
US20160017313A1 (en) 2013-03-15 2016-01-21 Moderna Therapeutics, Inc. Analysis of mrna heterogeneity and stability
WO2014144767A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Ion exchange purification of mrna
JP6702855B2 (ja) 2013-04-07 2020-06-03 ザ・ブロード・インスティテュート・インコーポレイテッド 個別化された新生物ワクチンの組成物及び方法
WO2015014375A1 (en) 2013-07-30 2015-02-05 Biontech Ag Tumor antigens for determining cancer therapy
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
EP3041934A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2015038892A1 (en) 2013-09-13 2015-03-19 Moderna Therapeutics, Inc. Polynucleotide compositions containing amino acids
WO2015043613A1 (en) 2013-09-26 2015-04-02 Biontech Ag Particles comprising a shell with rna
WO2015051169A2 (en) 2013-10-02 2015-04-09 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
EP3052479A4 (en) 2013-10-02 2017-10-25 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
WO2015058780A1 (en) 2013-10-25 2015-04-30 Biontech Ag Method and kit for determining whether a subject shows an immune response
EP3076994A4 (en) 2013-12-06 2017-06-07 Modernatx, Inc. Targeted adaptive vaccines
EP3053585A1 (en) 2013-12-13 2016-08-10 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
WO2015117620A1 (en) 2014-02-05 2015-08-13 Biontech Ag A cannula, an injection or infusion device and methods of using the cannula or the injection or infusion device
PT3134131T (pt) 2014-04-23 2022-03-24 Modernatx Inc Vacinas de ácidos nucleicos
WO2015172843A1 (en) 2014-05-16 2015-11-19 Biontech Diagnostics Gmbh Methods and kits for the diagnosis of cancer
WO2016062323A1 (en) 2014-10-20 2016-04-28 Biontech Ag Methods and compositions for diagnosis and treatment of cancer
EP4023755B1 (en) 2014-12-12 2023-04-26 CureVac SE Artificial nucleic acid molecules for improved protein expression
AU2015373404B2 (en) 2014-12-30 2021-09-09 CureVac SE Artificial nucleic acid molecules
WO2016155809A1 (en) 2015-03-31 2016-10-06 Biontech Rna Pharmaceuticals Gmbh Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell

Also Published As

Publication number Publication date
NZ617217A (en) 2016-04-29
BR112013029834A8 (pt) 2019-05-07
ZA201306944B (en) 2015-02-25
SI4223311T1 (sl) 2025-11-28
NZ742420A (en) 2022-10-28
HUE046152T2 (hu) 2020-02-28
PT4223311T (pt) 2025-08-21
RS64230B1 (sr) 2023-06-30
CN111286537A (zh) 2020-06-16
FI4223311T3 (fi) 2025-08-12
JP2023083289A (ja) 2023-06-15
JP2017018129A (ja) 2017-01-26
AU2019229434A1 (en) 2019-10-03
SMT202500304T1 (it) 2025-09-12
HUE062102T2 (hu) 2023-09-28
AU2012261237A1 (en) 2013-11-14
JP7297715B2 (ja) 2023-06-26
US20140178438A1 (en) 2014-06-26
PT3892295T (pt) 2023-06-01
SMT202300161T1 (it) 2023-07-20
DK4223311T3 (da) 2025-08-25
RU2670745C2 (ru) 2018-10-25
JP2014523406A (ja) 2014-09-11
US11248264B2 (en) 2022-02-15
CN105999250B (zh) 2020-03-10
SI3892295T1 (sl) 2023-09-29
RS62497B1 (sr) 2021-11-30
DK3892295T3 (da) 2023-05-15
AU2012261237B2 (en) 2017-06-01
US20210164034A1 (en) 2021-06-03
AU2022201275B2 (en) 2025-08-14
ES2897656T3 (es) 2022-03-02
JP2020128423A (ja) 2020-08-27
NZ718326A (en) 2020-05-29
CN105999250A (zh) 2016-10-12
SG10201911616QA (en) 2020-01-30
ES3038443T3 (en) 2025-10-13
LT3473267T (lt) 2021-11-25
MX2013013659A (es) 2014-02-27
AU2017213515A1 (en) 2017-08-31
CA2836494C (en) 2023-01-03
JP6456888B2 (ja) 2019-01-23
CA2836494A1 (en) 2012-11-29
JP2019050831A (ja) 2019-04-04
PL3892295T3 (pl) 2023-07-24
LT3892295T (lt) 2023-07-10
LT4223311T (lt) 2025-09-25
RS67093B1 (sr) 2025-09-30
PT3473267T (pt) 2021-11-02
CN103608033B (zh) 2016-06-15
US20220282322A1 (en) 2022-09-08
JP6444171B2 (ja) 2018-12-26
ES2746233T8 (es) 2020-03-13
AU2019229434B2 (en) 2021-12-16
CN103608033A (zh) 2014-02-26
JP2025109722A (ja) 2025-07-25
AU2017213515B2 (en) 2019-07-04
ES2746233T3 (es) 2020-03-05
SG193553A1 (en) 2013-10-30
RU2013157150A (ru) 2015-06-27
AU2022201275A1 (en) 2022-03-17
DK2714071T3 (da) 2019-09-16
ES2946072T3 (es) 2023-07-12
NZ730355A (en) 2022-10-28
HRP20250981T1 (hr) 2025-10-24
LT2714071T (lt) 2019-10-10
MX360823B (es) 2018-11-16
WO2012159754A3 (en) 2013-06-27
HRP20230443T1 (hr) 2023-09-15
US10738355B2 (en) 2020-08-11
PT2714071T (pt) 2019-09-30
PL4223311T3 (pl) 2025-09-08
WO2012159754A2 (en) 2012-11-29
HUE057608T2 (hu) 2022-06-28
SMT202100611T1 (it) 2022-01-10
FI3892295T3 (fi) 2023-05-10
RU2670745C9 (ru) 2018-12-13
MX2020011767A (es) 2020-11-24
SI3473267T1 (sl) 2022-01-31
BR112013029834A2 (pt) 2016-12-06
HRP20211595T1 (hr) 2022-01-21

Similar Documents

Publication Publication Date Title
MX386793B (es) Vacunas individualizadas para el cancer.
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
DK3030255T3 (da) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
BR112019007288A2 (pt) proteína heterodimérica biespecífica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica biespecífica e para tratar câncer em um paciente
CY1119055T1 (el) Αντισωματα που προσδενονται στην il-17a και στην il-17f
MX2022003698A (es) Composiciones de nanoparticulas y metodos para inmunoterapia.
CY1124685T1 (el) Εξατομικευμενα εμβολια για τον καρκινο
MX352324B (es) Vacunas multivalentes de nanovehiculos sinteticos.
MX2017001694A (es) Ligadores de nucleotidos modificados.
EA201291195A1 (ru) Усовершенствованная терапия рака на основе опухолеассоциированных антигенов, полученных из циклина d1
TN2014000206A1 (en) Antibody molecules having specificity for human ox40
EA201300915A1 (ru) Новый европейский штамм prrsv
PH12015500390B1 (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
EA201490381A1 (ru) Синтетические наноносители, которые стимулируют формирование гуморального иммунного ответа и иммунного ответа, опосредованного цитотоксическими т-лимфоцитами (ctl)
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
MX2013010475A (es) Composiciones inmunoterapeuticas de levadura-brachyuri.
MX2016007939A (es) Nueva vacuna de adn dirigida contra msln para la inmunoterapia de cancer.
CY1119173T1 (el) Νεα μορια αναστολεα jnk
CY1121859T1 (el) Μεθοδος παρασκευης αναστολεων συνθασης γλυκοζυλοκεραμιδης
MX362977B (es) Vectores para la transformacion de mycoplasma hyopneumoniae, cepas transformadas de m. hyopneumoniae, y uso correspondiente.
HK1218860A1 (zh) 卵巢癌疫苗及接种方法
MX375994B (es) Composicion farmaceutica que comprende particulas de plga-peg.
IL232172A0 (en) Antigen presenting cancer vaccine
UA116697C2 (uk) Композиція для запобігання зараженню видами роду mycoplasma
GB201017519D0 (en) Vaccines